Novartis says FDA gives accelerated approval for kidney-disease treatment

Novartis said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney disease.

Previous post Zillow names Jeremy Wacksman its new CEO as company narrows losses
Next post AppLovin’s big profit beat, positive outlook lift the app-monetization stock